National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Bortezomib

Synonyms

[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid

BORTEZOMIB

Bortezomib

LDP 341

MLN341

PS-341

PS341

Velcade

bortezomib

velcade

Definitions

A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1851

Accepted_Therapeutic_Use_For

Multiple Myeloma; Advanced Thyroid Cancer

ALT_DEFINITION

A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.

CAS_Registry

179324-69-7

CHEBI_ID

CHEBI:52717

Chemical_Formula

C19H25BN4O4

code

C1851

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

HemOnc

PCDC

DEFINITION

A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.

Display_Name

Bortezomib

FDA_UNII_Code

69G8BD63PP

FULL_SYN

[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid

BORTEZOMIB

Bortezomib

LDP 341

MLN341

PS-341

PS341

Velcade

bortezomib

velcade

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17778

Is_PCDC_AML_Authorized_Value_For_Variable

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C274

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Bortezomib

Legacy Concept Name

Bortezomib

Maps_To

Bortezomib

NCI_Drug_Dictionary_ID

43560

NSC Number

681239

PDQ_Closed_Trial_Search_ID

43560

PDQ_Open_Trial_Search_ID

43560

Preferred_Name

Bortezomib

prefixIRI

Thesaurus:C1851

Semantic_Type

Organic Chemical

Pharmacologic Substance

UMLS_CUI

C1176309

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2160

Delete Subject Author Type Created
No notes to display
Create mapping

Delete Mapping To Ontology Source
http://purl.obolibrary.org/obo/CHEBI_52717 OBA LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 FYPO LOOM
http://purl.bioontology.org/ontology/ATC/L01XG01 ATC LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000148811 NDFRT LOOM
http://purl.obolibrary.org/obo/OMIT_0001395 OMIT LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 EFO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 PDRO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 FIDEO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 DINTO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 HOIP LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 COVID-19 LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 BERO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 TXPO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 BIOMODELS LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 OBA LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 FYPO LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 CHEBI LOOM
http://purl.obolibrary.org/obo/CHEBI_52717 NIFSTD LOOM
http://purl.bioontology.org/ontology/PDQ/CDR0000043560 PDQ LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#C1176309 OCHV LOOM
http://www.phoc.org.cn/pmo/class/PMO_00015148 PMAPP-PMO LOOM
http://purl.obolibrary.org/obo/DRON_00018683 ODNAE LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#55829 OCHV LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000148811 ODAE LOOM
http://purl.bioontology.org/ontology/VANDF/4021393 VANDF LOOM
http://purl.obolibrary.org/obo/NCIT_C1851 BERO LOOM
http://purl.bioontology.org/ontology/MESH/D000069286 MESH LOOM
http://purl.obolibrary.org/obo/MESH_D000069286 BERO LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/407097007 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/RXNORM/358258 RXNORM LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#C400082 RH-MESH LOOM
https://go.drugbank.com/drugs/DB00188 MDM LOOM
http://purl.bioontology.org/ontology/NDDF/009985 NDDF LOOM
http://www.drugbank.ca/drugs/DB00188 FTC LOOM